HC Wainwright & Co. Maintains Neutral on Macrogenics, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a Neutral rating on Macrogenics (NASDAQ:MGNX) and raises the price target from $14 to $16.
March 11, 2024 | 10:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Neutral rating on Macrogenics, with an increased price target from $14 to $16.
The increase in price target from $14 to $16 by a reputable analyst firm like HC Wainwright & Co. suggests a positive outlook on the stock's value, potentially leading to short-term investor optimism and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100